Oncology

Identifying and reducing barriers to oncology clinical research at the site level.

Recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. In line with transforming patient care, we have also already begun to transform drug development.

ICON conducts clinical studies in both solid and haematological tumours including breast, lung, gastric, HCC, prostate, multiple myeloma, AML, lymphoma and leukaemia.

ICON services your oncology trial can benefit from include:

Commercialisation & Outcomes

Our Commercialisation and Outcomes consultants can advise you on developing market access and pricing strategies.

Explore

Medical Imaging

Medical imaging enables improved decision making, increased efficiency, and can reduce trial costs.

Explore

Site and Patient Recruitment

ICON's proven paradigm bridges the gap between patients and clinical research sites.

Explore

FIRECREST

FIRECREST digital solutions increase efficiency in clinical trials by driving site performance.

Explore

Laboratory Services

ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.

Explore

Transforming patient outcomes

The explosion of information about the genetic aberrations underlying cancer has led to several changes in the paradigm of how we develop drugs for this disease. We believe that transformation of the outcomes for patients with cancer will require detailed understanding of these genetic aberrations in each patient’s cancer at diagnosis.

Targeted therapies, novel immunotherapies and the ability to combine these agents together successfully will be important in the development of effective and tolerable treatment regimens.

Oncology survey

Understanding the complexities of Conducting Oncology Clinical Trials.

Share your feedback

With almost 40% of our projects focused in oncology, our project managers and clinical teams have a deep experience in the challenges of clinical development in this area.

Two thirds of oncology studies are in early phase

Two thirds of oncology studies are in early phase

Operationalised alternative study designs, such as the nCRM

Operationalised alternative study designs, such as the nCRM

Managing some of the largest global phase III registration studies

Managing some of the largest global phase III registration studies